Louis Gooren

Q: What Schools Are Affiliated With Louis Gooren

Louis Gooren is affiliated with the following schools: University of Amsterdam, Gulf Medical University, Vrije Universiteit Amsterdam, Utrecht University, Eindhoven University of Technology, Delft University of Technology, Radboud University Nijmegen

Louis Gooren's AcademicInfluence.com Rankings

Louis Gooren

Physics

#5067

World Rank

#6841

Historical Rank

physics Degrees

Download Badge

Physics

Louis Gooren's Degrees

PhD Physics University of Amsterdam
Masters Applied Physics Delft University of Technology
Bachelors Physics University of Amsterdam

Why Is Louis Gooren Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Louis J. G. Gooren was a Dutch endocrinologist known for his work with transsexual and transgender people. He treated over 2,200 transsexual people and was one of the first physicians to treat transgender youth.

(See a Problem?)

Louis Gooren's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. (2009) (928)
Endocrine Treatment of Gender‐Dysphoric/Gender‐Incongruent Persons: An Endocrine Society* Clinical Practice Guideline (2017) (899)
A sex difference in the human brain and its relation to transsexuality (1995) (711)
Investigation, treatment and monitoring of late-onset hypogonadism in males (2008) (703)
Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. (2009) (519)
Mortality and morbidity in transsexual subjects treated with cross‐sex hormones (1997) (473)
ENDOCRINE TREATMENT OF GENDER-DYSPHORIC/GENDER-INCONGRUENT PERSONS: AN ENDOCRINE SOCIETY CLINICAL PRACTICE GUIDELINE. (2017) (446)
Male-to-female transsexuals have female neuron numbers in a limbic nucleus. (2000) (427)
A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. (2011) (416)
Induction of insulin resistance by androgens and estrogens. (1994) (383)
Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. (2006) (369)
Transsexualism: a review of etiology, diagnosis and treatment. (1999) (340)
Docosahexaenoic acid concentrations are higher in women than in men because of estrogenic effects. (2004) (315)
Gender differences in behaviour: Activating effects of cross-sex hormones (1995) (296)
Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. (2008) (286)
Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects (2003) (279)
Investigation, treatment and monitoring of late-onset hypogonadism in males. (2009) (260)
Memory for emotional events: differential effects of centrally versus peripherally acting β-blocking agents (1998) (246)
Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. (1999) (225)
An epidemiological and demographic study of transsexuals in the Netherlands (1996) (214)
Endocrine aspects of male sexual dysfunctions. (2010) (208)
Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. (2006) (207)
Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. (2000) (198)
ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males (2009) (196)
Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. (1998) (192)
Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. (1997) (192)
Mortality and morbidity in transsexual patients with cross-gender hormone treatment. (1989) (189)
The treatment of adolescent transsexuals: changing insights. (2008) (185)
A ten-year safety study of the oral androgen testosterone undecanoate. (1994) (179)
Prevalence of Transsexualism in the Netherlands (1988) (177)
Clinical practice. Care of transsexual persons. (2011) (174)
Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. (2013) (174)
The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects. (1989) (174)
Activating effects of cross-sex hormones on cognitive functioning: a study of short-term and long-term hormone effects in transsexuals (1999) (169)
The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women (2005) (169)
Chronic renal failure and sexual functioning: clinical status versus objectively assessed sexual response. (1997) (165)
The biology of human psychosexual differentiation (2006) (164)
ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males (2009) (162)
Ovarian morphology in long‐term androgen‐treated female to male transsexuals. A human model for the study of polycystic ovarian syndrome? (1991) (159)
Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. (1998) (159)
Endocrine aspects of sexual dysfunction in men. (2004) (157)
In vivo effects of sex steroids on lymphocyte responsiveness and immunoglobulin levels in humans. (2000) (157)
Changing your sex changes your brain: influences of testosterone and estrogen on adult human brain structure (2006) (144)
EAU GuidelinesInvestigation, Treatment and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, and EAU Recommendations (2005) (140)
A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. (2008) (139)
Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review (2012) (135)
Endocrinology of Transgender Medicine. (2018) (133)
Estrogen-induced prolactinoma in a man. (1988) (132)
Investigation, treatment and monitoring of late-onset hypogonadism in males. (2005) (129)
Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. (2008) (129)
Hormone Treatment of the Adult Transsexual Patient (2005) (128)
Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. (2010) (127)
Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. (2008) (126)
Activating effects of androgens on cognitive performance: Causal evidence in a group of female-to-male transsexuals (1994) (119)
The prevalence of transsexualism in the Netherlands (1993) (118)
Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. (2005) (116)
IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. (2013) (114)
Transsexualism in Serbia: a twenty-year follow-up study. (2009) (107)
Psychological consequences. (2002) (106)
The Effects of Sex Steroids on Plasma Levels of Marker Proteins of Endothelial Cell Functioning (1998) (102)
Clinical review: Breast development in trans women receiving cross-sex hormones. (2014) (98)
The role of testosterone in the metabolic syndrome: A review (2009) (98)
Androgen levels and sex functions in testosterone-treated hypogonadal men (1987) (96)
Organizing and activating effects of sex hormones in homosexual transsexuals. (2002) (96)
Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. (2014) (95)
Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome (2008) (94)
The human hypothalamus in relation to gender and sexual orientation. (1992) (94)
Arterial compliance and distensibility are modulated by body composition in both men and women but by insulin sensitivity only in women (1999) (93)
Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration. (1998) (92)
PROLACTIN LEVELS AND PITUITARY ENLARGEMENT IN HORMONE‐TREATED MALE‐TO‐FEMALE TRANSSEXUALS (1988) (91)
The effect of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-1 in transsexuals. (1996) (89)
The age-related decline of androgen levels in men: clinically significant? (1996) (88)
A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up (2012) (87)
Transgender feminization of the facial skeleton. (2007) (86)
An Exploratory Study of the Effects of 12 Month Administration of the Novel Long-Acting Testosterone Undecanoate on Measures of Sexual Function and the Metabolic Syndrome (2007) (84)
The neuroendocrine response of luteinizing hormone to estrogen administration in heterosexual, homosexual, and transsexual subjects. (1986) (83)
Homosexual and bisexual identity in sex-reassigned female-to-male transsexuals (1993) (81)
The Role of Testosterone in the Etiology and Treatment of Obesity, the Metabolic Syndrome, and Diabetes Mellitus Type 2 (2010) (79)
Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. (2009) (79)
Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men (2009) (75)
Prostate cancer incidence in orchidectomised male‐to‐female transsexual persons treated with oestrogens (2014) (75)
The endocrinology of transsexualism: A review and commentary (1990) (75)
COGNITIVE ABILITY AND CEREBRAL LATERALISATION IN TRANSSEXUALS (1998) (73)
Hormonal and psychopharmacological interventions in the treatment of paraphilias: An update (1996) (72)
Changes in fat cell size and in vitro lipolytic activity of abdominal and gluteal adipocytes after a one-year cross-sex hormone administration in transsexuals. (1999) (71)
Birth order and sibling sex ratio in two samples of Dutch gender-dysphoric homosexual males (1996) (71)
Metastatic prostatic carcinoma in a male-to-female transsexual. (1998) (69)
Suprachiasmatic nucleus in aging, Alzheimer's disease, transsexuality and Prader-Willi syndrome. (1987) (69)
Transsexuals and competitive sports. (2004) (68)
Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. (2014) (68)
17β‐Oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals * (1992) (65)
Recent insights into androgen action on the anatomical and physiological substrate of penile erection. (2006) (64)
Serum testosterone level is the major determinant of the male-female differences in serum levels of high-density lipoprotein (HDL) cholesterol and HDL2 cholesterol. (1994) (63)
Male cross-gender behavior in Myanmar (Burma): A description of the acault (1992) (62)
Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals. (2004) (62)
Brain research, gender and sexual orientation. (1995) (62)
Late-onset hypogonadism. (2009) (62)
Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male Transsexuals (2006) (61)
Effects of cross-sex hormones on cerebral activation during language and mental rotation: An fMRI study in transsexuals (2008) (61)
Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. (2008) (61)
Five new cases of breast cancer in transsexual persons (2015) (58)
Androgen replacement therapy: present and future. (2004) (58)
The neuroendocrine response of luteinizing hormone to estrogen administration in the human is not sex specific but dependent on the hormonal environment. (1986) (58)
Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. (2009) (57)
Androgens and male behavior (2002) (56)
Androgen deficiency in the aging male: benefits and risks of androgen supplementation (2003) (56)
Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone (2008) (55)
Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. (2007) (55)
Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research (2007) (55)
Growth hormone substitution in adult growth hormone‐deficient men augments androgen effects on the skin (1997) (54)
The effect of androgen treatment on bone metabolism in female‐to‐male transsexuals (1996) (54)
Haemodialysis and testicular function. (1984) (53)
Oral estrogen treatment induces a decrease in expression of sialyl Lewis x on α1 glycoprotein in females and male-to-female transsexuals (1996) (53)
Sex steroids, insulin, and arterial stiffness in women and Men. (1999) (52)
Significance of oestrogens in male (patho)physiology. (2003) (52)
Endocrine aspects of ageing in the male (1998) (51)
Cross-sex hormone use, functional health and mental well-being among transgender men (Toms) and Transgender Women (Kathoeys) in Thailand (2015) (51)
Migraine prevalence in male to female transsexuals on hormone therapy (2004) (50)
Facial corrections in male to female transsexuals: a preliminary report on 16 patients. (1996) (50)
Human male sexual functions do not require aromatization of testosterone: A study using tamoxifen, testolactone, and dihydrotestosterone (1985) (48)
Diagnosis of prolactinoma in two male‐to‐female transsexual subjects following high‐dose cross‐sex hormone therapy (2015) (48)
Effects of estrogens only on the prostates of aging men. (1996) (48)
Management of female-to-male transgender persons: medical and surgical management, life expectancy (2014) (47)
Oral, but not transdermal, administration of estrogens lowers tissue-type plasminogen activator levels in humans without affecting endothelial synthesis. (2000) (46)
Androgens and Ankylosing Spondylitis: A Role in the Pathogenesis? (1999) (45)
Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals. (2003) (44)
The effect of beta-adrenergic blockade after encoding on memory of an emotional event (2002) (44)
The Feasibility of Endocrine Interventions in Juvenile Transsexuals (1996) (43)
Sex steroids and pulsatile luteinizing hormone release in men. Studies in estrogen-treated agonadal subjects and eugonadal subjects treated with a novel nonsteroidal antiandrogen. (1987) (43)
Signs of testicular insufficiency in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy: a retrospective study. (1997) (43)
Meningiomas in three male‐to‐female transgender subjects using oestrogens/progestogens and review of the literature (2016) (43)
The effects of sex-steroid administration on the pituitary-thyroid axis in transsexuals. (2006) (41)
Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. (2004) (41)
FOLLOW‐UP OF PROLACTIN LEVELS IN LONG‐TERM OESTROGEN‐TREATED MALE‐TO‐FEMALE TRANSSEXUALS WITH REGARD TO PROLACTINOMA INDUCTION (1985) (40)
Gonadal and adrenal sex steroids in ankylosing spondylitis. (2000) (39)
Gender and sexual orientation in relation to hypothalamic structures. (1992) (39)
Serum testosterone levels are not elevated in patients with ankylosing spondylitis. (1998) (39)
The impact of testosterone administration to female-to-male transsexuals on insulin resistance and lipid parameters compared with women with polycystic ovary syndrome. (2010) (39)
Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages (2009) (39)
Development of male gender identity/role and a sexual orientation towards women in a 46,XY subject with an incomplete form of the androgen insensitivity syndrome (1991) (38)
Clinical review: Ethical and medical considerations of androgen deprivation treatment of sex offenders. (2011) (38)
Transdermal testosterone delivery: testosterone patch and gel (2003) (38)
Safety of physiological testosterone therapy in women: lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy. (2010) (38)
Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood (2009) (38)
Effects of cross-sex hormonetreatment on emotionality in transsexuals (2001) (37)
Endocrine treatment of aging transgender people (2018) (35)
Androgen Replacement Therapy (2012) (35)
Androgens and estrogens in their negative feedback action in the hypothalamo-pituitary-testis axis: site of action and evidence of their interaction. (1989) (35)
Modulation of plasma endothelin levels by the menstrual cycle. (2000) (35)
Potential side effects of androgen deprivation treatment in sex offenders. (2009) (35)
Effect of a Single Dose of Levodopa on Sexual Response in Men and Women (2005) (34)
Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentrations are significantly increased after testosterone administration in female-to-male transsexuals. (2000) (33)
Oral Ethinyl Estradiol, but not Transdermal 17β-estradiol, Increases Plasma C-reactive Protein Levels in Men (2000) (33)
Estimating the contribution of the prostate to blood dihydrotestosterone. (2003) (32)
Exploration of functional health, mental well-being and cross-sex hormone use in a sample of Thai male-to-female transgendered persons (kathoeys). (2013) (32)
Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women. (1989) (31)
Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years (2014) (31)
Advances in testosterone replacement therapy. (2009) (31)
(Patho)physiology of cross‐sex hormone administration to transsexual people: the potential impact of male–female genetic differences (2015) (30)
Hormone Treatment in Transsexuals (1993) (30)
The dermatoglyphic characteristics of transsexuals: is there evidence for an organizing effect of sex hormones (2000) (29)
Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010 (2012) (29)
Testosterone administration increases adrenal response to adrenocorticotrophin (1994) (28)
Effects of gonadal androgens and oestrogens on adrenal androgen levels (1995) (28)
Three definitions of metabolic syndrome applied to a sample of young obese men and their relation with plasma testosterone (2008) (28)
Hormones, Metabolism, Aging and Men's Health (2008) (27)
Conjectures concerning cross-sex hormone treatment of aging transsexual persons. (2014) (27)
Long term hormonal treatment for transgender people (2017) (27)
Long-term safety of the oral androgen testosterone undecanoate. (1986) (26)
Effects of insulin infusion on endothelium-derived vasoactive substances (1996) (26)
Bone Development in Transgender Adolescents Treated With GnRH Analogues and Subsequent Gender-Affirming Hormones (2020) (26)
Androgens and male aging: Current evidence of safety and efficacy. (2010) (25)
Differences in reproductive endocrinology between Asian men and Caucasian men--a literature review. (2000) (25)
Oral estrogen treatment induces a decrease in expression of sialyl Lewis x on alpha 1-acid glycoprotein in females and male-to-female transsexuals. (1996) (24)
ORIGINAL RESEARCH—INTERSEX AND GENDER IDENTITY DISORDERS The Treatment of Adolescent Transsexuals: Changing Insights (2008) (24)
Effects of dehydroepiandrosterone administration on disease activity in patients with rheumatoid arthritis. (1998) (23)
Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study. (2009) (23)
Improvement of spermatogenesis after treatment with the antiestrogen tamoxifen in a man with the incomplete androgen insensitivity syndrome. (1989) (22)
The effect of cross-gender hormonal treatment on bone metabolism in male-to-female transsexuals. (1989) (22)
Hypogonadotropic hypogonadal men respond less well to androgen substitution treatment than hypergonadotropic hypogonadal men (1988) (22)
Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria. (2021) (22)
Theories of gender transpositions: A critique and suggestions for further research (1989) (22)
Estrogens in the Feedback Regulation of Gonadotropin Secretion in Men: Effects of Administration of Estrogen to Agonadal Subjects and the Antiestrogen Tamoxifen and the Aromatase Inhibitor δ‘‐Testolactone to Eugonadal Subjects (2009) (21)
Effects of Sex Steroids on the Neurotransmitter-Specific Aromatic Amino Acids Phenylalanine, Tyrosine, and Tryptophan in Transsexual Subjects (2008) (21)
Late onset hypogonadism of men is not equivalent to the menopause. (2014) (20)
Elevated sinistrality in transsexuals (1992) (20)
Divergent effects of the antiestrogen tamoxifen and of estrogens on luteinizing hormone (LH) pulse frequency, but not on basal LH levels and LH pulse amplitude in men. (1988) (19)
Clinical efficacy and safety of sildenafil citrate (Viagra) in a multi‐racial population in Singapore: A retrospective study of 1520 patients (2002) (19)
The Influence of Hormone Treatment on Psychological Functioning of Transsexuals (1993) (18)
Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3. (2005) (18)
Influence of exogenous oestrogen or (anti-) androgen administration on soluble transferrin receptor in human plasma. (2005) (18)
Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals. (2000) (17)
Sexual dimorphism and transsexuality: clinical observations. (1984) (16)
Decreased serum biochemical markers of muscle origin in patients with ankylosing spondylitis (1999) (16)
Improvement of the diabetic foot upon testosterone administration to hypogonadal men with peripheral arterial disease. Report of three cases (2009) (16)
The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals. (2006) (16)
Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options (2011) (16)
Visceral obesity, androgens and the risks of cardiovascular disease and diabetes mellitus (2001) (16)
Testosterone therapy in men with Crohn’s disease improves the clinical course of the disease: data from long-term observational registry study (2015) (15)
Effects of normalization of plasma testosterone levels in hypogonadal men on plasma levels and urinary excretion of asymmetric dimethylarginine (ADMA). (2008) (14)
Somatostatin inhibits prolactin release from the lactotroph primed with oestrogen and cyproterone acetate in man. (1984) (14)
Pulsatile luteinizing hormone release and ovarian steroid levels in female-to-male transsexuals compared to heterosexual women (1989) (14)
Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study. (2004) (14)
Effect of testosterone administration on serum and urine kallikrein concentrations in female-to-male transsexuals. (2006) (14)
The role of the urologist in the prevention and early detection of cardiovascular disease (2011) (14)
Author's response: The endocrine care of transsexual people. (2004) (14)
Effects of the pure antiandrogen RU 23.903 (anandron) on sexuality, aggression, and mood in male-to-female transsexuals (1989) (13)
Short-term patterns of pulsatile luteinizing hormone secretion do not differ between male-to-female transsexuals and heterosexual men (1988) (13)
Testosterone supplementation: why and for whom? (2003) (13)
Sexual Functioning in Chronic Renal Failure (1997) (12)
Olympic sports and transsexuals. (2008) (12)
The role of testosterone in erectile function and dysfunction (2006) (12)
Prolactin secretion in the human male is increased by endogenous oestrogens and decreased by exogenous/endogenous androgens. (1984) (11)
Safety aspects of androgen therapy (1990) (11)
Three cases of sex chromosome mosaicism with a nonfluorescent Y (1979) (11)
Hormones and sport: physiology, pharmacology and forensic science. (2008) (11)
Differential effects of cross-sex hormonal treatment on plasma asymmetric dimethylarginine (ADMA) in healthy male-to-female and female-to-male transsexuals. (2009) (11)
Osteoporosis and sex steroids (2007) (10)
Sex Reassignment: Endocrinological Interventions in Adults with Gender Dysphoria (2014) (10)
Estrogen positive feedback on LH secretion in transsexuality (1984) (10)
Studies on the prolactin-releasing capacity of luteinizing hormone releasing hormone in male subjects. (2009) (9)
Effects of normalization of plasma testosterone levels in hypogonadal men on plasma levels and urinary excretion of asymmetric dimethylarginine (ADMA) (2007) (9)
Androgenizing effects of low-dose cyclosporin in male patients with early RA. (1998) (8)
Patterns of serum cortisol levels in ovariectomized females with and without androgen administration. (1992) (8)
Dehydroepiandrosterone Sulfate in Patients with Rheumatoid Arthritis (1999) (8)
Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study (2017) (8)
Diagnosing hypogonadism and treating decisions in different parts of the world: shifts in patterns between 2006 and 2015 (2016) (8)
Administration of testosterone to elderly hypogonadal men with Crohn's disease improves their Crohn's Disease Activity Index: a pilot study (2010) (8)
Treatment of Gender Dysphoria (2006) (7)
Androgens in the Feedback Regulation of Gonadotropin Secretion in Men: Effects of Administration of Dihydrotestosterone to Eugonadal and Agonadal Subjects and of Spironolactone to Eugonadal Subjects * (2009) (7)
Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. (1999) (7)
Reversal of the LH response to oestrogen administration after orchidectomy in a male subject with the androgen insensitivity syndrome. (1987) (7)
New long-acting androgens (2003) (7)
Effects of short-term testosterone administration on variables of the metabolic syndrome, in particular aldosterone (2012) (7)
THE EFFECT OF ENDOGENOUS AND EXOGENOUS GONADOTROPHIN‐RELEASING HORMONE ON THE PROLACTIN RESPONSE TO TRH (1984) (7)
Psychological stress as a cause of intermittent gynecomastia. (1986) (7)
Obesity: new aspects (2008) (7)
Clubbed fingers: the claws we lost? (2004) (7)
Comorbidity of gender identity disorders. (2004) (7)
The sex difference of plasma homovanillic acid is unaffected by cross-sex hormone administration in transsexual subjects. (2005) (7)
Age, obesity and inflammation at baseline predict the effects of testosterone administration on the metabolic syndrome (2011) (6)
EFFECTS OF OPIATE RECEPTOR BLOCKADE ON GONADOTROPHIN SECRETION BEFORE AND AFTER ADMINISTRATION OF THE OESTROGEN RECEPTOR BLOCKER TAMOXIFEN IN EUGONADAL MEN (1988) (6)
The endocrine care of transsexual people - Response (2004) (6)
Testosterone and the brain (2007) (6)
Quality-of-life issues in the aging male (2000) (6)
The characteristics of late-onset hypogonadism, its prevalence, symptoms, and diagnosis (2006) (6)
Androgen treatment of female-to-male transsexuals (1998) (6)
Sexual Orientation in Men and Women (2009) (6)
The effect of cyproterone acetate alone and in combination with ethinylestradiol on the hypothalamic pituitary adrenal axis, prolactin and growth hormone release in male-to-female transsexuals. (1986) (6)
Visceral obesity, the metabolic syndrome, androgens and estrogens (2006) (6)
Serum and urine tissue kallikrein concentrations in male-to-female transsexuals treated with antiandrogens and estrogens. (2006) (6)
One and the same androgen for all? Towards designer androgens. (1999) (5)
Options of androgen treatment in the aging male (1999) (5)
Phenylbutazone can spuriously elevate unextracted testosterone assay results in patients with ankylosing spondylitis. (2000) (5)
[Treatment of young transsexuals in the Netherlands]. (2000) (5)
Frailty and its relationship to late onset hypogonadism (2007) (5)
Godlewski has drawn attention to the sex ratio of transsexuals requesting sexological treatment in Poland. (1989) (5)
The effect of 6 weeks of testosterone treatment on pulsatile luteinizing hormone secretion in eugonadal female-to-male transsexuals (1991) (5)
The significance of testosterone for fair participation of the female sex in competitive sports. (2011) (4)
Is there a hormonal basis for human homosexuality? (2011) (4)
Serum dehydroepiandrosterone sulphate levels in patients with early rheumatoid arthritis: positive association with C-reactive protein, but not with HLA-DR genotype. (1998) (4)
Associations of plasma androgens with suicidality among men and women: A 9-year longitudinal cohort study. (2020) (4)
Textbook of Men's Health and Aging, Second Edition (2007) (4)
Should cross-sex hormone treatment of transsexual subjects vary with ethnic group? (2014) (4)
Effects of short- and long-term administration of tamoxifen on hCG-induced testicular steroidogenesis in man: no evidence for an oestradiol-induced steroidogenic lesion. (1985) (4)
Diagnostic approach to the aging male (2002) (4)
Reply to Letter to the Editor: "Endocrine Treatment of Gender Dysphoric/Gender Incongruent Persons: An Endocrine Society* Clinical Practice Guideline". (2019) (4)
The Moscow study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the metabolic syndrome components and body composition (2010) (4)
The anti-oestrogen tamoxifen does not interfere with the dopaminergic control of prolactin and TSH release in normogonadotrophic oligozoospermic man. (1986) (3)
The naloxone-induced LH release in male-to-female transsexuals (1984) (3)
Effects of continuous LHRH infusion on plasma levels of LH and FSH in males, before and after oestrogen or anti-oestrogen treatment. (1986) (3)
Biological Determinants of Sexual Orientation (2012) (3)
Erotosexuality in a Man Lacking Physiological Postnatal Androgen Exposure (1988) (3)
[Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men]. (2000) (3)
Effects of naloxone infusion on plasma levels of LH, FSH, and in addition TSH and prolactin in males, before and after oestrogen or anti-oestrogen treatment. (1986) (3)
Risks of androgen therapy (2006) (3)
The Psychoneuroendocrinology of (Sexual) Aggression (2000) (3)
Hypertrophic osteoarthropathy: estrogens, prostaglandinE2, prostaglandin A2, and the inflammatory reflex (2018) (3)
Biomedical concepts of homosexuality: folk belief in a white coat. (1995) (3)
SECTION II: Diagnostics & Primary Assessment (2007) (3)
Comorbidity of Gender Identity Disorders [15] (multiple letters) (2004) (3)
Beneficial effects of 2 years of administration of parenteral testosterone undecanoate on the metabolic syndrome and on non-alcoholic liver steatosis and C-reactive protein (2010) (3)
Effects of physiological and supraphysiological doses of insulin on adrenal androgen levels. (1996) (3)
Body Politics: The Physical Side of Gender Identity (1991) (3)
How to optimise treatment of erectile dysfunction above and beyond the beneficial effects of a phosphodiesterase type 5 inhibitor (2008) (3)
Androgens, Use, Misuse, and Abuse (2013) (2)
[Transsexualism. I. Description, etiology, management]. (1992) (2)
[Concerns relating to care for transsexuals]. (2004) (2)
[Transsexualism. III. The second diagnostic phase: the real-life test]. (1992) (2)
Testosterone, depression and cognitive function (2007) (2)
The activating effects of cross-sex hormones on cognitive functioning: A study of short-term and long-term hormone effects in transsexuals (1998) (2)
Impact of Systemic Disease on Male Sexual Function (2007) (2)
Safety aspects of androgen treatment with 5alpha-dihydrotestosterone. (2007) (2)
Androgens and sexual functions in the human male. A study with cyproterone acetate (1984) (2)
The metabolic syndrome: when is testosterone treatment warranted (2008) (2)
Synthesis Plasminogen Activator Levels in Humans Without Affecting Endothelial Oral , but Not Transdermal , Administration of Estrogens Lowers Tissue-Type (2000) (2)
The effect of sex steroid hormones on serum leptin levels (1997) (2)
Introduction: Testosterone and the metabolic syndrome (2008) (2)
Aging men – The challenge ahead (2007) (1)
Concepts and methods of biomedical research into homosexuality and transsexualism (1994) (1)
[Some new aspects of the Klinefelter syndrome]. (2006) (1)
Exogenous androgens decrease the length of the luteal phase and increase the length of the follicular phase. (1985) (1)
Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex (2006) (1)
Can the administration of testosterone to men with late-onset hypogonadism be discontinued? (2008) (1)
Effects of steroid hormones on the secretion of hemostatic factors in, and angiogenic properties of, human vascular endothelial cells (1996) (1)
Short Title: Guidelines on the Endocrine Treatment of Transsexuals (2009) (1)
Clinical and endocrinological results of short term anandron treatment (1987) (1)
Androgen-resistance syndromes: considerations of gender assignment. (1997) (1)
Basal and LHRH‐Stimulated Gonadotropin Levels and the Circadian Rhythm of Testosterone and the Effect of Exogenous Testosterone Thereon (2009) (1)
Chapter 124 – The Endocrinology of Sexual Behavior and Gender Identity (2015) (1)
Where medicine meets the boundaries of manhood and womanhood. (2011) (1)
Comorbidities in Men with Erectile Dysfunction, with and without Hypogonadism (2010) (1)
Androgens, visceral obesity and the risks for cardiovascular disease and diabetes mellitus (2007) (1)
Risk of venous thromboembolism (VTE) in estrogen-treated male-to-female transsexuals: a review of literature and observations from 9 European centers for gender dysphoria (2011) (1)
Interaction of Inhibin and Estrogens on Basal and LRH‐stimulated Gonadotropin Levels (2009) (1)
85. Modulation of plasma endothelin levels by the menstrual cycle (1997) (1)
Cardiovascular and Respiratory System (2007) (1)
Recent perspectives on the age-related decline of testosterone (2008) (1)
Screening of the aging male (2007) (1)
Late Onset Hypogonadism and Lower Urinary Tract Symptoms: New Insights (2011) (1)
Program and Abstract Bone Morphometry 1992 The Sixth International MeetingThe effect of cross-gender hormonal treatment on bone metabolism in female-to-male transsexuals (1992) (0)
Effects of parenteral testosterone undecanoate administration on inflammatory markers: the Moscow study (2010) (0)
Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double‐blinded placebo‐controlled Moscow study (2011) (0)
Endocrinology of the aging male: an overview (2007) (0)
Visceral obesity, androgens and the risks of cardiovascular disease (2007) (0)
Delayed/Retarded Ejaculation (2013) (0)
Long-Term Effects of Normalization of Testosterone on Variables of the Metabolic Syndrome in Hypogonadal Men. (2010) (0)
Long-term effects of normalization of testosterone on variables of the metabolic syndrome in hypogonadal men: the moscow study (2011) (0)
The benefits and risks of androgen therapy in the aging male: prostate disease, lipids and vascular factors (2020) (0)
Testosterone Preparations for Treatment of Hypogonadal Men (2013) (0)
Diabetes mellitus and atherosclerosis (2003) (0)
4.05 – Sexual Orientation in Men and Women (2017) (0)
Hormonal Treatment of Male to Female Transgender (2019) (0)
Aging and body composition. (2007) (0)
MALE-TO-FEMAL EE TRANSSEXUAL PEOPLE HAVE FEMAL EE NEURON NUMBERS IN A LIMBI C NUCLEUS S (2007) (0)
Subject Index Vol. 64, Suppl. 2, 2005 (2005) (0)
The endocrine care of transsexual people. Authors' reply (2004) (0)
Central Nervous System and Psyche (2007) (0)
Etiology of Premature Ejaculation (2013) (0)
Testosterone administration in female-to-male transsexuals as a biological model studying hyperandrogenemia in women (2012) (0)
Safety study of long-acting parenteral testosterone undecanoate over 42 months: ISMH World Congress 2010 Abstract 190 (2010) (0)
2 MEN WITH LATE ONSET HYPOGONADISM OFTEN SUFFER FROM OTHER AILMENTS NEEDING TREATMENT AND VICE VERSA (2012) (0)
EFFECTS OF TESTOSTERONE SUPPLEMENTATION ON DEPRESSIVE SYMPTOMS, LOW VITALITY AND SEXUAL DYSFUNCTION IN HYPOGONADAL MEN WITH THE METABOLIC SYNDROME : THE MOSCOW STUDY (2010) (0)
The Moscow Study: a randomized, placebo-controlled, double-blind trial of parenteral testosterone undecanoate on the prostate status and blood count (2010) (0)
Upon continued testosterone administration to hypogonadal men, improvements in features of the metabolic syndrome are largest over the first 12-24 months but benefits are maintained (2010) (0)
[Use and abuse of androgens; side effects and risks]. (1990) (0)
681: Additional Therapeutic Action of Testosterone to the Favorable Effects of Exercise and Diet in Diabetes Type 2 (2007) (0)
Androgens and Endocrine Function in Aging Men: Effects on Sexual and General Health (2012) (0)
Hormone treatment and preventative strategies in aging men: whom to treat, when to treat and how to treat (2007) (0)
EFFECTS ON SEXUAL, DEPRESSIVE AND AGEING MALE SYMPTOMS IN HYPOGONADAL MEN TREATED WITH TESTOSTERONE SUPPLEMENTATION : RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (2010) (0)
Diagnostics & Primary Assessment (2007) (0)
Diabetes in the elderly male: nutritional aspects (2007) (0)
Effeets of the Pure Antiandrogen RU (Anandron) on Sexuality, Aggression, Mood in Male-to-Female Transsexuals (0)
Genitourinary system. (2007) (0)
A56 The benefits and risks of androgen therapy in the aging male (1996) (0)
New insights into androgen treatment of erectile dysfunction (2006) (0)
Testosterone treatment with testosterone undecanoate injections has beneficial effects on variables of the metabolic syndrome in elderly hypogonadal men (2007) (0)
DECREASE IN HDL2 CHOLESTEROL IN TESTOSTERONE-TREATED WOMEN DESPITE A REDUCTION IN SUBCUTANEOUS FAT. (1994) (0)
Medicalization of homosexuality (2015) (0)
Androgen deficiency and its management in elderly men (2007) (0)
Inhibin is unlikely to inhibit the evocation of an estrogenic positive feedback effect on LH in engonadal men (1989) (0)
Skin and Hair (2007) (0)
[Androgens, well-being and libido in women]. (2003) (0)
Louis Gooren is Endocrinologist and Professor of Transsexology, and Henriette Delamarre-van de Waal is Professor of Pediatric Endocrinology, both affiliated with the Hospital of the Vrieje Universiteit in Amsterdam, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. (1996) (0)
Is Waking Erectile Assessment (WEA) mandatory for evaluation of sexual function in patients with renal replacement therapy (1993) (0)
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations. (2011) (0)
Diabetes mellitus en atherosclerose (2003) (0)
Nutrition in older men (2007) (0)
Aging and the eye (2007) (0)
Nutrition, Digestion and Metabolism (2007) (0)
Comorbidity of gender identity disorders. Authors' reply (2004) (0)
3 CONTINUOUS IMPROVEMENTS OF THE METABOLIC SYNDROME UNDER TESTOSTERONE TREATMENT OVER 48 MONTHS IN THREE COHORTS, IN TOTAL 410 MEN (2012) (0)
Safety of 42 months of treatment with of long-acting parenteral testosterone undecanoate in men with late-onset hypogonadism (2011) (0)
Letter to the editor (1989) (0)
Testosterone administration to hypogonadal men for a period of up to 42 months improves features of the metabolic syndrome (2011) (0)
Biology of aging (2007) (0)

This paper list is powered by the following services:

Other Resources About Louis Gooren

en.wikipedia.org

What Schools Are Affiliated With Louis Gooren?

Louis Gooren is affiliated with the following schools:

Louis Gooren's Academic­Influence.com Rankings